According to SAM, 31 genes were identified as common to all the microarray platforms and therefore a common radiosensitivity signature.
The idea is to build a scale that can be combined across different microarray platforms, and therefore allows simultaneous examination of independent data sets.
In contrast, global gene expression changes after B cell receptor activation, for BAFF, LPS or IL21 stimulation have been described using different microarray-platforms. Therefore, a quantitative comparison is difficult.
Therefore, data from different microarray platforms are not directly comparable, and it is essential to use the original values of gene expression from each platform to derive an "effect size" estimate that is independent of platform, thus rendering the different platforms comparable.
Usually, different microarray platforms have multiple probes (or probe sets) that represent the same gene transcript; therefore, gene matching is necessary.
For early-stage cancer, no target gene is reported by using the GSE7670 platform; therefore, we report common drug target genes among the rest of the other three microarray platforms.
There are two major microarray platforms that have been widely used: cDNA microarrays and oligonucleotide microarrays.
Tan, P. K. et al. Evaluation of gene expression measurements from commercial microarray platforms.
Tan, P.K. et al. Evaluation of gene expression measurements from commercial microarray platforms.
Hester, S.D. et al. Comparison of comparative genomic hybridization technologies across microarray platforms.
